This is a StreetInsider.com Premium Only Page

Poseida Therapeutics (PSTX) – StreetInsider.com Reports

Apr 8, 2024 12:05 PM Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Mar 25, 2024 04:05 PM Poseida Therapeutics (PSTX) Appoints Syed Rizvi as Chief Medical Officer

Mar 13, 2024 04:05 PM Poseida Therapeutics (PSTX) Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

Mar 7, 2024 04:41 PM Poseida Therapeutics, Inc. (PSTX) Tops Q4 EPS by 12c

Jan 4, 2024 08:05 AM Poseida Therapeutics (PSTX) Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones

Dec 11, 2023 07:29 AM Poseida Therapeutics, Inc (PSTX) PT Raised to $10 at Piper Sandler

Dec 11, 2023 06:32 AM Poseida Therapeutics, Inc (PSTX) PT Raised to $20 at H.C. Wainwright

Dec 11, 2023 03:51 AM Poseida Therapeutics (PSTX) Presents Positive Early Results from its Phase 1 Trial of P-BCMA-ALLO1

Oct 9, 2023 04:30 PM Poseida Therapeutics (PSTX) Announces Leadership Transition

Aug 9, 2023 06:33 AM Poseida Therapeutics, Inc (PSTX) PT Lowered to $14 at Cantor Fitzgerald

Aug 8, 2023 05:39 PM Poseida Therapeutics, Inc. (PSTX) Tops Q2 EPS by 21c

Aug 7, 2023 09:08 AM Poseida Therapeutics (PSTX) Announces Strategic Investment by Astellas and Provides Business Update

Aug 7, 2023 08:55 AM Poseida Therapeutics (PSTX) Halted, News Pending

Jul 5, 2023 08:02 AM Poseida Therapeutics (PSTX) Announces FDA Clearance of Investigational NDA for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies

May 9, 2023 06:13 PM Poseida Therapeutics, Inc. (PSTX) Tops Q1 EPS by 16c

Apr 13, 2023 08:03 AM Poseida Therapeutics (PSTX) Appoints Rafael G. Amado to its Board

Mar 13, 2023 06:33 AM Poseida Therapeutics, Inc (PSTX) PT Lowered to $17 at Cantor Fitzgerald

Mar 9, 2023 05:06 PM Poseida Therapeutics, Inc. (PSTX) Misses Q4 EPS by 56c

Jan 31, 2023 04:07 PM Poseida Therapeutics (PSTX) Announces Board Changes

Jan 4, 2023 06:03 AM H.C. Wainwright Starts Poseida Therapeutics, Inc (PSTX) at Buy

Dec 6, 2022 06:42 AM Poseida Therapeutics (PSTX) to Present Early Phase 1 Trial Data of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO I-O

Nov 11, 2022 06:21 AM Poseida Therapeutics, Inc (PSTX) PT Lowered to $14 at BTIG

Aug 9, 2022 06:12 AM Poseida Therapeutics, Inc (PSTX) PT Raised to $11 at Piper Sandler

Aug 4, 2022 08:01 AM Poseida Therapeutics (PSTX) Prices 20M Share Offering at $3.50/sh

Aug 4, 2022 07:01 AM Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed

Aug 3, 2022 04:01 PM Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed

Aug 3, 2022 07:30 AM Poseida Therapeutics (PSTX) Announces Pact with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

Aug 3, 2022 07:25 AM Poseida Therapeutics (PSTX) Halted, News Pending

Jun 29, 2022 04:06 PM Poseida Therapeutics (PSTX) Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products

May 18, 2022 08:03 AM Poseida Therapeutics (PSTX) Appoints Charles M. Baum to its Board

May 13, 2022 04:18 PM Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight

Apr 7, 2022 04:42 PM Poseida Therapeutics (PSTX) Announces Chief Medical Officer Resignation

Feb 18, 2022 06:36 AM Cantor Fitzgerald Starts Poseida Therapeutics, Inc (PSTX) at Overweight

Feb 17, 2022 08:06 AM Poseida Therapeutics (PSTX) to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium

Jan 10, 2022 08:04 AM Poseida Therapeutics (PSTX) Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen

Jan 7, 2022 06:33 AM Cantor Fitzgerald Starts Poseida Therapeutics, Inc (PSTX) at Overweight

Dec 20, 2021 08:04 AM Poseida Therapeutics (PSTX) Announces FDA Clearance of IND Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors

Oct 13, 2021 08:04 AM Poseida Therapeutics (PSTX) announces Johanna Mylet will serve as Chief Financial Officer

Oct 12, 2021 11:07 AM Poseida Therapeutics, Inc (PSTX) PT Raised to $19 at Piper Sandler

Oct 12, 2021 07:01 AM Poseida Therapeutics (PSTX) Enters Research Collaboration with Takeda (TAK) for Novel Non-Viral In Vivo Gene Therapies

Aug 31, 2021 10:10 AM Poseida Therapeutics (PSTX) Presents Positive Preliminary Results from Phase 1 Trial of P-PSMA-101

Aug 13, 2021 04:34 PM Poseida Therapeutics (PSTX) Files $300M Mixed Shelf

Jul 26, 2021 08:05 AM Poseida Therapeutics (PSTX) Appoints Cynthia Collins to its Board

May 18, 2021 08:53 AM Poseida Therapeutics, Inc (PSTX) PT Lowered to $17 at Piper Sandler

May 17, 2021 04:25 PM UPDATE: BTIG Starts Poseida Therapeutics (PSTX) at Buy (correction)

May 11, 2021 08:08 AM Poseida Therapeutics (PSTX) Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs

Dec 17, 2020 08:12 AM Poseida Therapeutics (PSTX) Adds Luke Corning to Board

Nov 2, 2020 08:04 AM Poseida Therapeutics (PSTX) Reports Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

Oct 21, 2020 08:09 AM Poseida Therapeutics (PSTX), TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

Aug 18, 2020 09:29 AM Pre-Open Stock Movers 08/18: (SE) (RXT) (VNDA) Higher; (PSTX) (NBR) (KSS) Lower (more...)